腫瘍関連マクロファージにおけるトール型受容体経路の治療標的化
Lei Wang1, Yinghua Li2, Zehua He1
1Shanghai Frontiers Science Center for Drug Target Identification and Delivery, and the Engineering Research Center of Cell and Therapeutic Antibody of the Ministry of Education, School of Pharmaceutical Sciences, State Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, Shanghai, China.
Cytokine & growth factor reviews
|February 20, 2026
まとめ
トール型受容体 (TLRs) は,腫瘍関連マクロファージ (TAMs) を再プログラムして,がんと闘うことができます. CARマクロファージと抗体-TLR結合体などの新しい戦略は,がん治療のためにTLRを活用する正確な方法を提供します.
科学分野:
- 免疫学 免疫学とは
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
背景:
- 腫瘍関連マクロファージ (TAMs) は,腫瘍微環境 (TME) の主要な調節体であり,免疫抑制と治療抵抗を促進します.
- トール型受容体 (TLR) は,先天性免疫にとって極めて重要であり,TAMを再プログラムするための潜在的な標的を提供します.
- 複雑なTMEとその制約により,TLRシグナリングセラピーの翻訳には課題があります.
研究 の 目的:
- マクロファージにおけるTLRシグナル伝達の分子基礎をレビューする.
- 腫瘍の文脈におけるTLR活性化の二重効果を分析する.
- 現在の治療戦略を評価し,TLRベースのTAM調節の臨床開発のためのロードマップを提案する.
主な方法:
- マクロファージとTAMにおけるTLRシグナル伝達に関する既存の文献のレビュー.
- 腫瘍免疫と進行に対するTLR活性化の影響の分析.
- CARマクロファージと抗体-TLR結合体を含む新興治療プラットフォームの評価.
主要な成果:
- TLRの信号伝達経路は,TME内で複雑で文脈に依存しています.
- TAMはTLRの活性化によって調節できるが,代謝と耐受性の障害に直面する.
- 新しい治療アプローチは,TLRベースのTAMの再プログラムが,正確かつ安全に可能であることを示しています.
結論:
- TAMのTLRをターゲットにすることは,がん免疫療法の有望な戦略です.
- CARマクロファージと抗体-TLR結合体の進歩により,治療の精度が向上しています.
- 翻訳障壁を克服し,がん治療のためのTLRベースのTAM調節を最適化するために,さらなる臨床開発が必要です.
関連する概念動画
The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Cytotoxic T Cells-mediated Immune Response
7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K


